Photopheresis for Early-Stage Mycosis Fungoides
This study is investigating if a treatment called photopheresis can help people with early-stage cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides. Photopheresis uses a medicine called UVADEX® (methoxsalen) and a device called THERAKOS® CELLEX to treat the blood outside the body, then return it. This treatment is currently used for later stages of CTCL, but researchers want to see if it can be effective earlier. The study aims to enroll 74 participants who are at least 18 years old and weigh less than 40 kg. Success will be measured by how many participants show an overall response to the treatment after one year. The study's current status is unclear.
- Study design
- This is an interventional study planning to enroll 74 participants. It is investigating a specific immunotherapy treatment.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for at least one year to measure the overall response rate.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Photopheresis in Early-stage Mycosis Fungoides
At a glance
Conditions
NCT05680558
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Columbia University Irving Medical Center
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Larisa Geskin, MD · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall Response Rate1 Year
Overall response rate at 1 year measured by the modified skin-weighted assessment tool (mSWAT) in accordance with Olsen et al criteria for response in clinical trial. Measurable lesions are defined as those that can be accurately measured in at least one dimension.